Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
Status:
Completed
Trial end date:
2017-10-20
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of
free and vascular endothelial growth factor (VEGF)-bound abicipar following single and
multiple intravitreal injections of abicipar pegol in treatment-naïve patients with
neovascular age-related macular degeneration (AMD).